Showing results (111-120 of 208) with videos related to

Sort By:
Pageof 21
The Lancet. Oncology|October 27, 2018
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trialFrank Stephen Hodi, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2013
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanomaPaolo A Ascierto, David Minor, Antoni Ribas, et al.
European Journal of Dermatology : EJD|January 31, 2019
Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE studyJohan Hansson, Karen Bartley, Thomas Karagiannis, et al.
Journal of the American Academy of Dermatology|December 21, 2022
Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohortPerrine Rousset, Stéphane Dalle, Laurent Mortier, et al.
Clinical and Translational Science|June 20, 2024
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b studyJoaquina C Baranda, Debbie Robbrecht, Ryan Sullivan, et al.
The Lancet. Oncology|July 27, 2019
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 studyCaroline Robert, Antoni Ribas, Jacob Schachter, et al.
Cancer|July 4, 2025
Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800)Alexander M Menzies, Pamela Salman, Osvaldo Arén Frontera, et al.
The New England Journal of Medicine|April 21, 2015
Pembrolizumab versus Ipilimumab in Advanced MelanomaCaroline Robert, Jacob Schachter, Georgina V Long, et al.
Journal for Immunotherapy of Cancer|February 26, 2025
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020Paolo A Ascierto, Hao Tang, Sonia Dolfi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2024
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial DataGeorgina V Long, Evan J Lipson, F Stephen Hodi, et al.
Pageof 21